Actively Recruiting
Study of Transcranial Direct Current Stimulation to Reduce Cannabis Use in Adults With Schizophrenia
Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2026-05-06
110
Participants Needed
8
Research Sites
25 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of transcranial direct current stimulation tDCS on cannabis use disorder in people with schizophrenia. This study aims to see if 10 sessions of specific brain stimulation can reduce cannabis consumption, craving, addiction severity, and schizophrenia symptoms, while improving overall functioning. The study also explores possible changes in cognitive functions and brain connectivity related to these effects. Participants will receive either active tDCS or sham non-active stimulation using a Neurocan DC-Stimulator Plus device. Electrodes will be placed on the scalp to stimulate specific brain areas twice daily for 20 minutes each session over 5 consecutive weekdays. The control group will undergo a sham procedure that mimics the sensations of active stimulation without therapeutic effects. During the study, researchers will monitor cannabis use and craving scores at 3 and 6 months, hospitalizations, and brain connectivity changes through imaging studies. Participants will be assessed for schizophrenia symptoms and overall functioning. The study involves random assignment to treatment groups and double-blind masking to ensure unbiased results. Total involvement includes follow-up visits and evaluations over a 6-month period.
CONDITIONS
Brief Title
Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia
Research Team
A
Aurelia GAY, MD
B
Béatrice DEYGAS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
